Dr. Susan Klaeger is a Principal Scientist and Group Lead of Immunopeptidomics and Surface Proteomics at Genentech, a role she has held since 2022. Her research is focused on applied proteomics, specializing in immunopeptidomics and proteogenomics to discover and validate novel cancer antigens and biomarkers for therapeutic development. She holds a PhD from the Technical University of Munich and the German Cancer Consortium, where she applied chemoproteomics approaches to study selectivity of clinical kinase inhibitors, followed by a postdoctoral fellowship at The Broad Institute of MIT and Harvard, where her research focused on improving detection of MHC presented peptides, generation of large scale datasets for AI/ML approaches and proteogenomic integration to the discovery of MHC presented peptides derived from novel, unannotated open reading frames.